RTI licenses Athersys proprietary stem cell technology |

RTI licenses Athersys proprietary stem cell technology

RTI Biologics and Athersys Announce Collaboration in the Orthopedic Market (Press Release)

Under the agreement, Athersys will receive a $3 million license fee and is also eligible to receive payments up to a cumulative total of $37.5 million as follows: $2 million contingent upon successful achievement of certain development and commercialization milestones, and an additional maximum total of $35.5 million contingent upon achievement of certain cumulative revenue milestones, which will reflect the ultimate commercial success of the product in this fast growing market. In addition, Athersys will receive tiered royalties from the distribution of implants using Athersys’ technologies.

Leave a Reply

Your email address will not be published. Required fields are marked *